Spain connects medicine cost-effectiveness unit to economic austerity push
This article was originally published in Scrip
In what appears to be the most nakedly overt connection between government desires to reduce medicines spending and the assessment of health technology, a new package of austerity measures approved yesterday by Spain's congress will – amongst other moves - include the creation of a new committee that will look at the cost-effectiveness of medicines and healthcare products.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.